Company intelligence / Profile preview

GestVision

Groton, Connecticut, United Statesgestvision.com ↗

Ownership: Private
Employees: ~3
Development stage: Other

Overview

GestVision has developed the Congo Red Dot (CRD) point-of-care test to rapidly identify preeclampsia in pregnant women. Clinical studies have demonstrated its utility for antenatal triage and rapid diagnosis by detecting protein misfolding biomarkers associated with preeclampsia.

The CRD test addresses an unmet need for fast, reliable diagnosis of this serious pregnancy complication.

Therapeutic areas: Women's Health
Modalities: Device (diagnostic test)
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on GestVision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GestVision.

Explore the full profile